top of page
AdobeStock_1310274797_EDIT.jpg

Our Leadership Team

Our leadership team combines deep scientific expertise, global industry experience, and academic excellence from top institutions - united by a shared commitment to innovation and patient impact.

Ethan Shen, PhD

Chairman & CEO

Dr. Ethan Shen is a scientist, entrepreneur, and investor dedicated to accelerating the translation of scientific discovery into real-world healthcare solutions. As Chairman and Chief Executive Officer of YD Bio, he guides the company’s strategic vision across oncology diagnostics, ophthalmology, and exosome-based therapeutics. His career spans more than two decades of building and leading biotech ventures, including co-developing an anti–PD-L1 cancer vaccine in collaboration with the University of Southern California and supporting early-stage innovation through research foundations and venture investment. At YD Bio, Dr. Shen is focused on expanding access to transformative technologies that improve outcomes and extend lives.

“At YD Bio, we believe in the potential of science to shape a healthier future. We are committed to making those advances accessible, delivering meaningful impact for patients who need them most.”

Ethan Shen

Ph.D. in Translational Medicine,  Academia Sinica
and Taipei Medical University, Taipei, Taiwan

Graduate Certificate in Financial Research Baruch College/ New York 

EMBA, FUDAN University and National Taiwan University

EXPERTISE:

  • Translational Medicine 

  • New Drug Development

​

  • Medical-grade Health Product Development 

  • Financial Management

Benjamin Zhang

School of Medicine, Taipei Medical University, Taipei, Taiwan 

Benjamin Zhang, MD

CMO

Dr. Benjamin Zhang is a physician-scientist and translational medicine leader dedicated to advancing next-generation therapies from bench to bedside. As Chief Medical Officer of YD Bio, he drives the company’s clinical and regulatory strategy, ensuring that innovations in cancer diagnostics, immunotherapy, and regenerative medicine are developed with scientific rigor and delivered with patient impact. His expertise spans IND preparation, cell and exosome therapy development, and global clinical trial execution, with a career rooted in bridging academic research and industry application. At YD Bio, Dr. Zhang is focused on shaping a robust medical pipeline that addresses urgent unmet needs and positions the company at the forefront of biotech innovation.

“At YD Bio, my mission is to translate scientific excellence into real-world treatments - bringing hope, access, and better outcomes to patients worldwide.”

EXPERTISE:

  • Cell Engineering

  • Clinical-grade Cell Manufacturing

  • ​​New Drug Development

​​​

  • IND Submission

  • Clinical Trials

​​​​​

  • Translational Medicine

Edmund Hen, MSc, FCA, CPA

CFO

Mr. Edmund Hen is an accomplished financial executive with extensive experience in corporate finance, capital markets, and business strategy. As Chief Financial Officer at YD Bio, he leads financial planning, regulatory compliance, and investor relations, ensuring transparency and disciplined growth. His expertise in capital management and strategic business development has been pivotal in advancing the company’s expansion initiatives.

“At YD Bio, financial discipline is the foundation for turning science into impact. By aligning resources with innovation, we are committed to creating lasting value for patients and stakeholders alike.”

Edmund Hen

Master of Science in Professional Accounting University College London, UK

Bachelor of Science in Accounting and Finance University of East Anglia, UK 

EXPERTISE:

  • Corporate Financial Management

  • Capital Market Operations

​​​

  • Financial Strategy & Fundraising

​​​​​

  • International Accounting​ and Audit Experience

  • Internal Controls and Compliance

bottom of page